80 related articles for article (PubMed ID: 16394123)
1. Design and development of thermolytic DNA oligonucleotide prodrugs.
Grajkowski A; Pedras-Vasconcelos J; Ausín C; Verthelyi D; Beaucage SL
Ann N Y Acad Sci; 2005 Nov; 1058():26-38. PubMed ID: 16394123
[TBL] [Abstract][Full Text] [Related]
2. Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs.
Grajkowski A; Pedras-Vasconcelos J; Wang V; Ausín C; Hess S; Verthelyi D; Beaucage SL
Nucleic Acids Res; 2005; 33(11):3550-60. PubMed ID: 15972797
[TBL] [Abstract][Full Text] [Related]
3. Solid-phase synthesis of thermolytic DNA oligonucleotides functionalized with a single 4-hydroxy-1-butyl or 4-phosphato-/thiophosphato-1-butyl thiophosphate protecting group.
Grajkowski A; Ausín C; Kauffman JS; Snyder J; Hess S; Lloyd JR; Beaucage SL
J Org Chem; 2007 Feb; 72(3):805-15. PubMed ID: 17253799
[TBL] [Abstract][Full Text] [Related]
4. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates.
Puig M; Grajkowski A; Boczkowska M; Ausín C; Beaucage SL; Verthelyi D
Nucleic Acids Res; 2006; 34(22):6488-95. PubMed ID: 17130156
[TBL] [Abstract][Full Text] [Related]
5. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
Zimmermann S; Dalpke A; Heeg K
Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
[TBL] [Abstract][Full Text] [Related]
6. Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides.
Kamstrup S; Frimann TH; Barfoed AM
Antiviral Res; 2006 Oct; 72(1):42-8. PubMed ID: 16678920
[TBL] [Abstract][Full Text] [Related]
7. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
[TBL] [Abstract][Full Text] [Related]
8. Oral and intraperitoneal administration of phosphorothioate oligodeoxynucleotides leads to control of Cryptosporidium parvum infection in neonatal mice.
Barrier M; Lacroix-Lamandé S; Mancassola R; Auray G; Bernardet N; Chaussé AM; Uematsu S; Akira S; Laurent F
J Infect Dis; 2006 May; 193(10):1400-7. PubMed ID: 16619188
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of CpG oligonucleotides and chenopodium album extract reverse IgG2a/IgG1 ratios and increase IFN-gamma and IL-10 productions in a murine model of asthma.
Mousavi T; Salek Moghadam A; Falak R; Tebyanian M
Iran J Allergy Asthma Immunol; 2008 Mar; 7(1):1-6. PubMed ID: 18322305
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma mediates suppression of erythropoiesis but not reduced red cell survival following CpG-ODN administration in vivo.
Thawani N; Tam M; Chang KH; Stevenson MM
Exp Hematol; 2006 Nov; 34(11):1451-61. PubMed ID: 17046564
[TBL] [Abstract][Full Text] [Related]
11. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
[TBL] [Abstract][Full Text] [Related]
12. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction.
Bleich A; Janus LM; Smoczek A; Westendorf AM; Strauch U; Mähler M; Hedrich HJ; Fichtner-Feigl S; Schölmerich J; Falk W; Hofmann C; Obermeier F
Gastroenterology; 2009 Jan; 136(1):278-87. PubMed ID: 18952084
[TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
[TBL] [Abstract][Full Text] [Related]
14. [A study on the mechanisms of mycobacterial clearance induced by CpG-oligodeoxynucleotides in mice].
Ren T; Liang YJ; Cai YY; Li CY; Mei J; Yuan ZH; Tao MF; Tian M; Zhao B
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jan; 31(1):46-50. PubMed ID: 18366907
[TBL] [Abstract][Full Text] [Related]
15. In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets.
Linghua Z; Xingshan T; Fengzhen Z
Vaccine; 2008 Jan; 26(2):224-33. PubMed ID: 18063448
[TBL] [Abstract][Full Text] [Related]
16. Thermolytic release of covalently linked DNA oligonucleotides and their conjugates from controlled-pore glass at near neutral pH.
Grajkowski A; Cieślak J; Kauffman JS; Duff RJ; Norris S; Freedberg DI; Beaucage SL
Bioconjug Chem; 2008 Aug; 19(8):1696-706. PubMed ID: 18646834
[TBL] [Abstract][Full Text] [Related]
17. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
18. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
19. In vivo priming heterophil innate immune functions and increasing resistance to Salmonella enteritidis infection in neonatal chickens by immune stimulatory CpG oligodeoxynucleotides.
He H; Genovese KJ; Swaggerty CL; Nisbet DJ; Kogut MH
Vet Immunol Immunopathol; 2007 Jun; 117(3-4):275-83. PubMed ID: 17434210
[TBL] [Abstract][Full Text] [Related]
20. Thermolytic properties of 3-(2-pyridyl)-1-propyl and 2-[N-methyl-N-(2-pyridyl)]aminoethyl phosphate/thiophosphate protecting groups in solid-phase synthesis of oligodeoxyribonucleotides.
Cieślak J; Beaucage SL
J Org Chem; 2003 Dec; 68(26):10123-9. PubMed ID: 14682709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
